Chengdu Olymvax Biopharmaceuticals Management
Management criteria checks 4/4
Chengdu Olymvax Biopharmaceuticals' CEO is Shaowen Fan, appointed in Jan 2010, has a tenure of 15.83 years. directly owns 3.86% of the company’s shares, worth CN¥353.43M. The average tenure of the management team and the board of directors is 15.8 years and 9.4 years respectively.
Key information
Shaowen Fan
Chief executive officer
CN¥734.2k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 15.8yrs |
| CEO ownership | 3.9% |
| Management average tenure | 15.8yrs |
| Board average tenure | 9.4yrs |
Recent management updates
Recent updates
Subdued Growth No Barrier To Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) With Shares Advancing 35%
Mar 06
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Using Too Much Debt?
Feb 12Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected
Oct 09We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt
Sep 30What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You
Jun 24Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?
May 28Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely
Apr 18These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively
Mar 26CEO
Shaowen Fan (72 yo)
Mr. Shaowen Fan is Chairman of the Board & GM of Chengdu Olymvax Biopharmaceuticals Inc. from January 2010. Mr. Fan joined the Chengdu Olymvax Biopharmaceuticals Inc. in 2010.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 15.8yrs | CN¥734.20k | 3.86% CN¥ 353.4m | |
| CFO & Deputy GM | 16.8yrs | CN¥641.90k | 0.11% CN¥ 10.0m | |
| Director & Deputy GM | no data | CN¥621.30k | 0.15% CN¥ 13.8m | |
| Secretary of the Board & Deputy GM | 9.4yrs | CN¥637.40k | 0.19% CN¥ 17.6m | |
| Accounting supervisor | no data | no data | no data |
Experienced Management: 688319's management team is seasoned and experienced (15.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & GM | 15.8yrs | CN¥734.20k | 3.86% CN¥ 353.4m | |
| Director & Deputy GM | 15.8yrs | CN¥621.30k | 0.15% CN¥ 13.8m | |
| Independent Director | less than a year | no data | no data | |
| Director | 12.4yrs | CN¥55.90k | 0.014% CN¥ 1.3m | |
| Chairman of Supervisory Board | 9.4yrs | no data | 6.38% CN¥ 583.9m | |
| Vice Chairman of the Board | 15.8yrs | CN¥641.50k | 7.53% CN¥ 689.4m | |
| Independent Director | less than a year | no data | no data | |
| Employee Representative Supervisor | 3.5yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: 688319's board of directors are considered experienced (9.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 09:53 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chengdu Olymvax Biopharmaceuticals Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yifei Chen | Citic Securities Co., Ltd. |
| Zhu Chen | Citic Securities Co., Ltd. |
| Xibing Chen | Guosen Securities Co., Ltd. |